Boomerang Medical

Executive Summary

Boomerang Medical is a women-led, private bioelectronic medicine company pioneering neuromodulation therapy for autoimmune diseases, with a primary focus on Inflammatory Bowel Disease (IBD) including Crohn’s disease and ulcerative colitis. The company’s technology uses electrical stimulation of the vagus nerve to modulate the inflammatory reflex, offering a non-pharmacological approach for patients unresponsive to conventional therapies. Boomerang’s lead device has received FDA Breakthrough Device Designation, underscoring its potential to address significant unmet needs. Headquartered in Mountain View, California, the company operates as a Company-In-Residence at Fogarty Innovation, a well-known medtech incubator. The IBD market exceeds $20 billion and is growing, with current treatments often losing efficacy or causing systemic side effects. Neuromodulation presents a targeted, drug-free alternative with a favorable safety profile. With Breakthrough Device Designation, Boomerang may benefit from expedited development and regulatory review, positioning it to capitalize on the expanding bioelectronic medicine field. However, the company remains pre-revenue and early-stage. Key upcoming milestones include the initiation of pivotal clinical trials, potential FDA approval of a pivotal study, and securing additional funding or partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Pivotal Clinical Trial for IBD70% success
• Q2 2026FDA Approval of Investigational Device Exemption (IDE) for Pivotal Study80% success
• H2 2026Series A or B Funding Round or Strategic Partnership60% success